AU2001284261A1 - Vaccine against microbial pathogens - Google Patents

Vaccine against microbial pathogens

Info

Publication number
AU2001284261A1
AU2001284261A1 AU2001284261A AU8426101A AU2001284261A1 AU 2001284261 A1 AU2001284261 A1 AU 2001284261A1 AU 2001284261 A AU2001284261 A AU 2001284261A AU 8426101 A AU8426101 A AU 8426101A AU 2001284261 A1 AU2001284261 A1 AU 2001284261A1
Authority
AU
Australia
Prior art keywords
heat shock
vaccine
present
shock protein
repressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284261A
Other languages
English (en)
Inventor
Camilo Anthony Leo Selwyn Colaco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Immunobiology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Ltd filed Critical Immunobiology Ltd
Publication of AU2001284261A1 publication Critical patent/AU2001284261A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001284261A 2000-09-04 2001-09-04 Vaccine against microbial pathogens Abandoned AU2001284261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0021757.0A GB0021757D0 (en) 2000-09-04 2000-09-04 Vaccine against microbial pathogens
GB0021757.0 2000-09-04
PCT/GB2001/003964 WO2002020045A2 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Publications (1)

Publication Number Publication Date
AU2001284261A1 true AU2001284261A1 (en) 2002-03-22

Family

ID=9898866

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284261A Abandoned AU2001284261A1 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Country Status (15)

Country Link
US (1) US20050232946A1 (https=)
EP (1) EP1315518B1 (https=)
JP (1) JP2004508339A (https=)
CN (1) CN1452495A (https=)
AT (1) ATE450270T1 (https=)
AU (1) AU2001284261A1 (https=)
CA (1) CA2421229A1 (https=)
DE (1) DE60140681D1 (https=)
DK (1) DK1315518T3 (https=)
ES (1) ES2337653T3 (https=)
GB (1) GB0021757D0 (https=)
IL (1) IL154727A0 (https=)
PT (1) PT1315518E (https=)
WO (1) WO2002020045A2 (https=)
ZA (1) ZA200301759B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928264B2 (en) * 2004-09-21 2011-04-19 Astellas Pharma Inc. Aminoalcohol derivatives
CN101522213A (zh) 2006-09-01 2009-09-02 Csl有限公司 引起或诱导免疫应答的方法
WO2009021291A1 (en) * 2007-08-16 2009-02-19 The University Of Sydney Mycobacterium vaccine formulation
NZ583377A (en) 2007-10-12 2013-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
MX2013012165A (es) * 2011-04-20 2014-06-11 Mico Bio Inc Composicion y metodo para mejorar una respuesta inmune.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3020226B2 (ja) * 1986-08-18 2000-03-15 ブリティッシュ・テクノロジー・グループ・リミテッド ワクチン
US5776724A (en) * 1988-10-24 1998-07-07 Yale University Chaperonin-mediated protein folding
JPH03204820A (ja) * 1989-10-12 1991-09-06 Nippon Saibai Suisan Kk エビ類の細菌性疾病予防ワクチン及びその製造法
WO1995014093A1 (en) * 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH0748398A (ja) * 1993-08-03 1995-02-21 Nippon Oil Co Ltd 変性蛋白質の再生方法及び変性蛋白質再生剤
US6872542B1 (en) * 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CZ394297A3 (cs) * 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US7022328B1 (en) * 1995-11-30 2006-04-04 Australian Pork Limited Therapeutic and diagnostic compositions
IN183280B (https=) * 1996-09-20 1999-10-30 Univ New Mexico
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6500434B1 (en) * 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
NZ509127A (en) * 1998-06-19 2004-01-30 Merieux Oravax Use of LT (E. coli) and CT (cholera toxin) for inducing immune responses against helicobacter infection
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
CA2363146A1 (en) * 1999-02-22 2000-08-31 Solomon Langermann Caulobacter lps immunoadjuvant
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
US6677139B1 (en) * 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
WO2001078772A1 (en) * 2000-04-17 2001-10-25 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
US6932985B2 (en) * 2000-10-10 2005-08-23 Auburn University Azide method and composition for controlling deleterious organisms
WO2002059156A2 (en) * 2000-12-22 2002-08-01 Medimmune, Inc. Therapeutic compounds structurally-linked to bacterial polypeptides
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US8088569B2 (en) * 2002-03-01 2012-01-03 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
EP1539223A2 (en) * 2002-05-02 2005-06-15 University of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes

Also Published As

Publication number Publication date
ATE450270T1 (de) 2009-12-15
CA2421229A1 (en) 2002-03-14
IL154727A0 (en) 2003-10-31
JP2004508339A (ja) 2004-03-18
GB0021757D0 (en) 2000-10-18
ES2337653T3 (es) 2010-04-28
WO2002020045A3 (en) 2002-10-31
US20050232946A1 (en) 2005-10-20
DE60140681D1 (de) 2010-01-14
CN1452495A (zh) 2003-10-29
EP1315518A2 (en) 2003-06-04
PT1315518E (pt) 2010-03-05
DK1315518T3 (da) 2010-04-19
WO2002020045A2 (en) 2002-03-14
ZA200301759B (en) 2004-06-22
EP1315518B1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
ATE315090T1 (de) Impfstoffherstellung des bacillus anthracis schutzantigens
AU2001284261A1 (en) Vaccine against microbial pathogens
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
ATE173166T1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
BR0103887A (pt) Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
WO2001063278A3 (en) Antigenic fragments associated with stress-induced proteins and their use as vaccines
ATE542544T1 (de) Pro-apoptotische bakterielle impfstoffe zur verbesserung der zellulären immunantwort
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
WO2005012538A3 (en) Accelerated vaccination
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
ZA200201359B (en) Vaccines from infectious agents.
BRPI0309787E2 (pt) Polipeptídeo isolado, composição de vacina anti-carrapato de espécies múltiplas, molécula de cdna isolada, vetor de expressão, célula isolada, vacina anti-carrapato de espécie múltipla, e, método de induzir uma resposta imune em um mamífero contra a infestação de carrapato de espécie múltipla e seus patógenos associados
CA2366056A1 (en) Non-spreading pestivirus
NO20062469L (no) Streptococcus phocae vaksine
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2004073603A3 (en) Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
WO2002067982A3 (en) Mycobacterial vaccines
AU1853995A (en) Vaccine compositions
ZA200201357B (en) Vaccine against intra-cellular pathogens.
WO2006037383A8 (en) Piscirickettsia salmonis antigens and use thereof
CU23358B7 (es) Vacuna que comprende una proteína cemento de garrapata
CU22986A1 (es) Uso de las proteínas cry de bacillus thuringiensis como agentes inmunoestimuladores y vectores para la presentación de epitopes vacunales
HK1075842A (en) Nanoemulsion vaccines